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als in 14 countries to access unpublished information and assess the acceptability 
of different MEA types across Europe. Outputs were developed into a vaccines 
specific MEA framework and guidance for implementation. Results: To date, 
there is very little experience with vaccine MEAs in Europe; however, interest-
ing value-added service examples were identified (e. g. educational campaign 
support). The vaccine-specific MEA framework developed (aligned with cur-
rent taxonomy) focused on financial schemes (e. g. staggered entry approaches, 
volume-based discounts, price-volume agreements), coverage with evidence 
development and value-added services (e. g. vaccination implementation sup-
port). Pay-for-performance MEAs were less applicable. Budget holder feedback 
in selected countries confirmed their interest in co-creating such MEA/service 
approaches with vaccine companies. ConClusions: To enable decision makers 
to continue investing in innovative vaccines that address public health needs, a 
shift towards new value-based acquisition models is key. A broader, more flexible 
approach to vaccines access, including MEAs, can address the needs of budget 
holders and other external stakeholders as well as manufacturers.
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objeCtives: Vaccines face increasing reimbursement and access challenges in 
many European markets. Decision makers are facing uncertainties in terms of 
budget impact planning, vaccines’ expected impact and vaccination implementa-
tion. This has led to major delay in the population access to vaccination, and to 
commoditization of some vaccinations. However, innovation in vaccines access 
has been more limited than for pharmaceuticals, where there is a longer history 
of adapting to pricing and access pressure. Building on the experience of managed 
entry agreements (MEAs) used for drugs, the project aimed to develop a framework 
of MEAs and value-added services specifically applicable to vaccines. Methods: 
Literature and web searches were performed to document MEA taxonomy and 
identify real world European MEA examples for pharmaceuticals and vaccines. 
This was followed by an on-line/telephone survey with SPMSD access profession-
